Kiril Malovitski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kiril Malovitski has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Eli Sprecher
Division of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
9 shared publications - Liat Samuelov
Division of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
8 shared publications - Ofer Sarig
Division of Dermatology, Tel Aviv Medical Center, Tel Aviv, Israel
8 shared publications - Janan Mohamad
Division of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
6 shared publications - Sari Assaf
Division of Dermatology Tel Aviv Medical Center Tel Aviv Israel
5 shared publications - Alon Peled
Division of Dermatology Tel Aviv Sourasky Medical Center Tel Aviv Israel
3 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Wiley in Pediatric Dermatology
A Germline Missense Variant in the NSDHL Gene Underlies Inflammatory Linear Verrucous Epidermal Nevus
Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare skin disorder characterized by pruritic, erythematous, and scaly plaques following Blaschko's lines. Known genetic causes include somatic variants in CARD14 and GJA1 . In addition, a similar phenotype of congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) nevus has been associated with germline pathogenic variants in NSDHL encoding a NAD(P)‐dependent steroid dehydrogenase‐like protein essential for cholesterol biosynthesis. Here we report a case of ILVEN caused by a previously unreported germline pathogenic variant in NSDHL .
- 11 September 2026
- Published by Wiley in Pediatric Dermatology
Open AccessA Germline Missense Variant in the NSDHL Gene Underlies Inflammatory Linear Verrucous Epidermal Nevus
Inflammatory linear verrucous epidermal nevus (ILVEN) is a rare skin disorder characterized by pruritic, erythematous, and scaly plaques following Blaschko's lines. Known genetic causes include somatic variants in CARD14 and GJA1 . In addition, a similar phenotype of congenital hemidysplasia with ichthyosiform nevus and limb defects (CHILD) nevus has been associated with germline pathogenic variants in NSDHL encoding a NAD(P)‐dependent steroid dehydrogenase‐like protein essential for cholesterol biosynthesis. Here we report a case of ILVEN caused by a previously unreported germline pathogenic variant in NSDHL .
- Open Access
- 13 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3102-3111.e3
An ITGB4 variant modifies the severity of ITGA3-associated interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa (ILNEB)
- 13 June 2026
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (11) , 3102-3111.e3
Open AccessAn ITGB4 variant modifies the severity of ITGA3-associated interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa (ILNEB)
- Open Access
- 14 January 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (1) , e70206
Defective Function of Inhibitor of κB Kinase Subunit Beta Associated With Multiple Immune‐Mediated Disorders
Abnormal NF‐κB activity has been previously implicated in a range of immune‐mediated disorders. Here, we aimed to elucidate the genetic basis underlying the co‐occurrence of vitiligo, Addison's disease and granuloma annulare in a 43‐year‐old woman. Whole‐exome sequencing identified a heterozygous splice‐site variant (c.1364+1G>A, p.Met455fsTer1) in IKBKB , encoding the Inhibitor of κB kinase subunit beta (IKKβ), predicted to result in a premature stop codon. Immunoblotting of keratinocytes transfected with the mutant construct demonstrated the presence of a truncated form of IKKβ. Using a luciferase reporter assay under the control of NF‐κB–responsive element, we demonstrated significantly reduced activity of the mutant protein compared to wild‐type, supporting a loss‐of‐function mechanism. In line with this observation, the mutant protein was found to result in decreased expression levels of genes known to be regulated by NF‐κB. Furthermore, HeLa cells transfected with the p.Met455fsTer1 variant or IKBKB ‐targeted siRNA exhibited markedly reduced levels of p105 and its processed form p50, compared with HeLa cells transfected with wild‐type IKBKB or control siRNA, respectively. Collectively, these findings indicate that a loss‐of‐function effect in IKBKB may underlie the co‐occurrence of a number of immune‐mediated disorders through disruption of NF‐κB signalling.
- 14 January 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (1) , e70206
Open AccessDefective Function of Inhibitor of κB Kinase Subunit Beta Associated With Multiple Immune‐Mediated Disorders
Abnormal NF‐κB activity has been previously implicated in a range of immune‐mediated disorders. Here, we aimed to elucidate the genetic basis underlying the co‐occurrence of vitiligo, Addison's disease and granuloma annulare in a 43‐year‐old woman. Whole‐exome sequencing identified a heterozygous splice‐site variant (c.1364+1G>A, p.Met455fsTer1) in IKBKB , encoding the Inhibitor of κB kinase subunit beta (IKKβ), predicted to result in a premature stop codon. Immunoblotting of keratinocytes transfected with the mutant construct demonstrated the presence of a truncated form of IKKβ. Using a luciferase reporter assay under the control of NF‐κB–responsive element, we demonstrated significantly reduced activity of the mutant protein compared to wild‐type, supporting a loss‐of‐function mechanism. In line with this observation, the mutant protein was found to result in decreased expression levels of genes known to be regulated by NF‐κB. Furthermore, HeLa cells transfected with the p.Met455fsTer1 variant or IKBKB ‐targeted siRNA exhibited markedly reduced levels of p105 and its processed form p50, compared with HeLa cells transfected with wild‐type IKBKB or control siRNA, respectively. Collectively, these findings indicate that a loss‐of‐function effect in IKBKB may underlie the co‐occurrence of a number of immune‐mediated disorders through disruption of NF‐κB signalling.
- Open Access
- 19 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1596-1604.e2
Pathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia
- 19 November 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1596-1604.e2
Open AccessPathogenic variants affecting peptidyl arginine deiminase 3 and its major substrates underlie central centrifugal cicatricial alopecia
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- 1 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 619-641
Top Cited PapersOpen AccessNonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term ‘harlequin ichthyosis’ evokes potentially stigmatizing images. Similarly, the word ‘ichthyosis’ is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
- Top Cited PapersOpen Access
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.
- 4 April 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 592-618
Top Cited PapersOpen AccessSyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Since the 2010 classification of ichthyoses, our understanding of hereditary epidermal differentiation disorders (EDDs) has markedly increased, allowing for consideration of new therapeutic targets based on disease pathogenesis. A new gene- and protein product function-based classification focuses on shared mechanisms of disease pathogenesis, with the possibility that grouped disorders may respond similarly to new therapeutics. These EDDs have been subdivided into syndromic (sEDD), nonsyndromic with features limited to skin and appendages, and predominantly palmoplantar skin involvement (nonsyndromic and syndromic). sEDDs have clinically important extracutaneous features related to the gene alteration. Often, recognition based on skin manifestations facilitates early gene-based diagnosis, discussion of prognosis, genetic counselling and the initiation of therapy. All sEDDs are rare; the most common are STS-sEDD (formerly known as X-linked ichthyosis) and SPINK5-sEDD (formerly known as Netherton syndrome). Given the rarity, frequent association with early demise and variable clinical features of sEDDs, the natural history of the diseases with advancing age and genotype–phenotype relationships are poorly defined. Of the 51 sEDDs, associated neurological (n = 36; 71%) and/or ophthalmological (n = 25; 49%) findings are most common, and 39% (n = 20) have associated hair abnormalities. The widespread use of topical lovastatin for cholesterol synthesis-related sEDDs represents the prototype of pathogenesis-based therapy. This concept of upstream inhibition to prevent metabolite accumulation and supplementation with the pathway end product potentially applies to other sEDDs, such as those affecting ceramide synthesis and transport. Topical or systemically administered inhibition of activated pathways is another potential approach, exemplified by the emerging treatment of SPINK5-sEDD with kallikrein inhibitors. Many sEDDs may be amenable to gene editing or the introduction of functional cDNA. However, even systemic treatments targeting cutaneous diseases may not address extracutaneous manifestations that arise during embryological development.
- Open Access
- 20 February 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (5)
HMCN1 variants aggravate epidermolysis bullosa simplex phenotype
Epidermolysis bullosa simplex (EBS) refers to a heterogeneous group of inherited skin disorders characterized by blister formation within the basal cell layer. The disease is characterized by marked variations in phenotype severity, suggesting co-inheritance of genetic modifiers. We identified three deleterious variants in HMCN1 that co-segregated with a more severe phenotype in a group of 20 individuals with EBS caused by mutations in KRT14, encoding keratin 14 (K14). HMCN1 codes for hemicentin-1. Protein modeling, molecular dynamics simulations, and functional experiments showed that all three HMCN1 variants disrupt protein stability. Hemicentin-1 was found to be expressed in human skin above the BMZ. Using yeast-2-hybrid, co-immunoprecipitation, and proximity ligation assays, we found that hemicentin-1 binds K14. Three-dimensional skin equivalents grown from hemicentin-1–deficient cells were found to spontaneously develop subepidermal blisters, and HMCN1 downregulation was found to reduce keratin intermediate filament formation. In conclusion, hemicentin-1 binds K14 and contributes to BMZ stability, which explains the fact that deleterious HMCN1 variants co-segregate with a more severe phenotype in KRT14-associated EBS.
- 20 February 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (5)
Open AccessHMCN1 variants aggravate epidermolysis bullosa simplex phenotype
Epidermolysis bullosa simplex (EBS) refers to a heterogeneous group of inherited skin disorders characterized by blister formation within the basal cell layer. The disease is characterized by marked variations in phenotype severity, suggesting co-inheritance of genetic modifiers. We identified three deleterious variants in HMCN1 that co-segregated with a more severe phenotype in a group of 20 individuals with EBS caused by mutations in KRT14, encoding keratin 14 (K14). HMCN1 codes for hemicentin-1. Protein modeling, molecular dynamics simulations, and functional experiments showed that all three HMCN1 variants disrupt protein stability. Hemicentin-1 was found to be expressed in human skin above the BMZ. Using yeast-2-hybrid, co-immunoprecipitation, and proximity ligation assays, we found that hemicentin-1 binds K14. Three-dimensional skin equivalents grown from hemicentin-1–deficient cells were found to spontaneously develop subepidermal blisters, and HMCN1 downregulation was found to reduce keratin intermediate filament formation. In conclusion, hemicentin-1 binds K14 and contributes to BMZ stability, which explains the fact that deleterious HMCN1 variants co-segregate with a more severe phenotype in KRT14-associated EBS.
- 23 September 2022
- Published by Morressier GmbH
ESDR261 - A novel skin phenotype resulting from heterozygous deletion of six keratin genes
The phenotypic spectrum of genodermatoses is continuously expanding. Three individuals were referred because of a highly unusual phenotype compri | POSTER
- 23 September 2022
- Published by Morressier GmbH
ESDR261 - A novel skin phenotype resulting from heterozygous deletion of six keratin genes
The phenotypic spectrum of genodermatoses is continuously expanding. Three individuals were referred because of a highly unusual phenotype compri | POSTER
- 3 August 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (10) , 2879-2887
Autosomal recessive congenital ichthyosis caused by a pathogenic missense variant in CLDN1
Autosomal recessive congenital ichthyosis (ARCI) refers to a large and genetically heterogenous group of non-syndromic disorders of cornification featuring diffuse scaling. Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis (ILVASC) syndrome is a rare autosomal recessive syndromic form of ichthyosis. The disease usually results from premature termination codon-causing pathogenic variants in CLDN1 encoding CLAUDIN-1 (CLDN1). We used whole exome sequencing (WES), Sanger sequencing, 3D protein modeling, Western blotting, and immunofluorescence confocal microscopy to delineate the genetic basis of ichthyosis in two siblings with ichthyosis but no other ectodermal abnormalities. One of the two siblings underwent liver transplantation in early childhood due to biliary atresia. Both patients were found to carry a homozygous missense pathogenic variant, c.242G>A (p.Arg81His), in CLDN1. The variant resulted in decreased CLDN1 expression in patient skin. 3D protein modeling predicted that p.Arg81His induces deleterious conformational changes. Accordingly, HaCaT cells transfected with a construct expressing the mutant CLDN1 cDNA featured decreased levels and mislocation of CLDN1 as compared with cells expressing the wildtype cDNA. In conclusion, we describe the first pathogenic missense variant in CLDN1 shown to result in ARCI.
- 3 August 2022
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (10) , 2879-2887
Autosomal recessive congenital ichthyosis caused by a pathogenic missense variant in CLDN1
Autosomal recessive congenital ichthyosis (ARCI) refers to a large and genetically heterogenous group of non-syndromic disorders of cornification featuring diffuse scaling. Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis (ILVASC) syndrome is a rare autosomal recessive syndromic form of ichthyosis. The disease usually results from premature termination codon-causing pathogenic variants in CLDN1 encoding CLAUDIN-1 (CLDN1). We used whole exome sequencing (WES), Sanger sequencing, 3D protein modeling, Western blotting, and immunofluorescence confocal microscopy to delineate the genetic basis of ichthyosis in two siblings with ichthyosis but no other ectodermal abnormalities. One of the two siblings underwent liver transplantation in early childhood due to biliary atresia. Both patients were found to carry a homozygous missense pathogenic variant, c.242G>A (p.Arg81His), in CLDN1. The variant resulted in decreased CLDN1 expression in patient skin. 3D protein modeling predicted that p.Arg81His induces deleterious conformational changes. Accordingly, HaCaT cells transfected with a construct expressing the mutant CLDN1 cDNA featured decreased levels and mislocation of CLDN1 as compared with cells expressing the wildtype cDNA. In conclusion, we describe the first pathogenic missense variant in CLDN1 shown to result in ARCI.